Drugmakers and the rest of the scientific community can and should benefit from the careful disclosure of FDA review data, including clinical trial reports that industry and the agency now keep closely guarded, FDA Commissioner Margaret Hamburg says.

Device companies will continue to develop products abroad as long as financial and regulatory conditions overseas are more favorable than in the U.S., warned experts at the Food & Drug Law Institute annual meeting in Washington, D.C.

Full clinical trial reports with raw data should be publicly available, but regulatory authorities must develop engagement and standards to ensure meta- and re-analyses of data are of high quality, a group of European regulators say.